Canopy Growth Corp

Canopy Growth Corp(CGC)股票分析

$0.975

-0.020 (-2.00%)收盘时

Loading chart…
High
1.000
Open
0.990
VWAP
0.98
Vol
2.42M
Mkt Cap
508.24M
Low
0.966
Amount
2.37M
EV/EBITDA, TTM
-9.36

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

AI analysis of Canopy Growth Corp (CGC)

hold

Canopy Growth Corp is currently not a strong buy due to its low current price of $0.9995 and an RSI of 38.823, indicating it is nearing oversold territory but not yet a clear buy signal. The forward P/E ratio of 20.37 suggests high future earnings expectations, but the recent insider selling has increased by 187.19%, which raises concerns about confidence in the stock. The main risk is the negative sentiment from analysts and the ongoing losses, with a net income loss of -157.11 million CAD in the latest quarter.

估值指标

The current forward P/E ratio for Canopy Growth Corp (CGC) is 20.37, compared to its 5-year average forward P/E of -2.38.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.38
Current P/E
20.37
高估
7.66
低估
-12.42

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-276.36
Current EV/EBITDA
-9.36
高估
448.12
低估
-1000.83

Forward P/S

Fair
5Y Average P/S
3.17
Current P/S
1.26
高估
5.75
低估
0.59

Alphio AI Price Scenarios for CGC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CGC

$1.78

情景价格

B

Base

Base · 50%CGC

$1.69

情景价格

B

Bear

Bear · 25%CGC

$1.41

情景价格

事件时间线

2026-08-07 (ET)

07:30:00

Company Reports Q1 Revenue of C$100.4M

2026-07-16 (ET)

09:00:00

REalloys Inc Borrow Rate Increases to 29.55%

2026-06-30 (ET)

09:00:00

Latest Data Shows Wendy's Borrow Rate Rises to 34.75%

2026-06-26 (ET)

09:00:00

KULR Technology Group Borrow Rate Increases to 65.52%

2026-06-25 (ET)

09:01:00

Angion Biomedica Borrow Rate Increases to 183.97%

资讯

CGC FAQ — answered by Alphio AI

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Canopy Growth Corp is currently not a strong buy due to its low current price of $0.9995 and an RSI of 38.823, indicating it is nearing oversold territory but not yet a clear buy signal. The forward P/E ratio of 20.37 suggests high future earnings expectations, but the recent insider selling has increased by 187.19%, which raises concerns about confidence in the stock. The main risk is the negative sentiment from analysts and the ongoing losses, with a net income loss of -157.11 million CAD in the latest quarter.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始